Mexico has strong potential to become a clinical research leader worldwide. We have all the elements, such as population, disease profile, ensemble of trained investigators and the local representation of the international bio-pharmaceutical and CRO industries, as well as the support of COFEPRIS and the most recognized agencies worldwide. However, we need to assimilate all the elements together in the most synergistic manner to significantly elevate the total number of the active trials in the coming years. Research sites should orient their activities to quality and performance to attract more research projects. Mexico accounts for less than 1 percent of all clinical research worldwide, a very low rate compared to other countries.
Deyanira Chiñas Ramírez
The Mexican pharma industry has not remained ‘asleep’ in the face of exclusions and bad decisions made by the government, writes Deyanira Chiñas.
Seven months in, INSABI has faced many challenges besides COVID-19. Here are some facts about the government’s venture toward universal healthcare.
View from the Top
President of ANFAM Cecilia Bravo explains the current challenges of medicine manufactures and the Association's work to overcome them
Generics are always an attractive alternative for those who need medication at accessible prices, be they individuals or healthcare systems.
Accelerium Clinical Research
Mexico Health Review spoke with three CROs about the best strategies that can help Mexico become an international hub for clinical research.